Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: August 5, 2009
Last updated: June 24, 2015
Last verified: June 2015
The purpose of this study is to determine how well tolerated and safe AZD5069 is at different dose levels in healthy male and/or females. The study will also investigate how quickly AZD5069 is absorbed into and cleared by the body.

Condition Intervention Phase
Drug: AZD5069
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 After Single Ascending Doses in Healthy Male and/or Female Subjects

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Safety and tolerability of AZD5069 assessing vitals signs (blood pressure, pulse rate,body temperature), ECG,laboratory variables (including high sensitivity C-reactive protein, circulating neutrophils), continuous cardiac monitoring using telemetry. [ Time Frame: Baselines assessments at Visit 1 (enrolment). Assessments pre-dose at Visit 2 and at protocol defined time-points post-dose. Follow up assessments at Visit 3. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetic profile: concentration of AZD5069 in blood [ Time Frame: Samples collected at Visit 2 from pre-dose and at regular protocol defined intervals up to 96 hours post-dose. ] [ Designated as safety issue: No ]
  • Measurement of the effect of AZD5069 on circulating neutrophils [ Time Frame: Samples collected at Visit 2 from pre-dose and at regular protocol defined intervals up to 96 hours post-dose. ] [ Designated as safety issue: No ]
  • Pharmacodynamic profile: assessment of ex vivo GROa stimulated CD11b expression on neutrophils in whole blood [ Time Frame: Samples collected at Visit 2 from pre-dose and at regular protocol defined intervals up to 48 hours post-dose. ] [ Designated as safety issue: No ]

Enrollment: 203
Study Start Date: July 2009
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active
AZD5069 oral solution
Drug: AZD5069
Single dose of oral solution.
Placebo Comparator: Placebo
Placebo oral solution
Drug: Placebo
Single dose of oral solution.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provision of signed and dated, written informed consent
  • Healthy male or female (of non child bearing potential) caucasian subjects aged 18 to 65 years with suitable veins for cannulation or repeated venepuncture
  • Body mass index of between 18 and 30 kg/m2 inclusive

Exclusion Criteria:

  • Subjects must not have any clinically significant disease or disorder, which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results, or the subjects ability to participate in the study
  • Subjects must not have any history of gastrointestinal, liver or kidney disease, or any other condition known to interfere with how drugs are absorbed, used or eliminated by the body
  • Subjects must not have had any significant illness or medical/surgical procedures or injuries with 4 weeks of administration of the investigational product
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00953888

United Kingdom
Research Site
Nottingham, United Kingdom
Sponsors and Collaborators
Principal Investigator: Andrew Sparrow, BSc, BMedSci, BM,BS AstraZeneca Clinical Pharmacology Unit, Queens Medical Centre, Nottingham NG7 2UH
  More Information

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT00953888     History of Changes
Other Study ID Numbers: D3550C00001 
Study First Received: August 5, 2009
Last Updated: June 24, 2015
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by AstraZeneca:
Healthy volunteer
Single ascending dose
Healthy volunteer study processed this record on May 26, 2016